pubmed-article:11299809 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:11299809 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
pubmed-article:11299809 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
pubmed-article:11299809 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
pubmed-article:11299809 | lifeskim:mentions | umls-concept:C0039286 | lld:lifeskim |
pubmed-article:11299809 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
pubmed-article:11299809 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
pubmed-article:11299809 | lifeskim:mentions | umls-concept:C0021665 | lld:lifeskim |
pubmed-article:11299809 | lifeskim:mentions | umls-concept:C1306673 | lld:lifeskim |
pubmed-article:11299809 | pubmed:issue | 1B | lld:pubmed |
pubmed-article:11299809 | pubmed:dateCreated | 2001-4-12 | lld:pubmed |
pubmed-article:11299809 | pubmed:abstractText | Tamoxifen suppresses insulin-like growth factor-1 (IGF-1) plasma levels in early and advanced breast cancer patients. Relationships between tamoxifen (GH) and IGF-1 are complex and not completely described yet. The present investigation was performed to evaluate the effect of acute and chronic tamoxifen administration on GH response to growth hormone-releasing hormone (GHRH), as well as on IGF-1 serum levels. | lld:pubmed |
pubmed-article:11299809 | pubmed:language | eng | lld:pubmed |
pubmed-article:11299809 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11299809 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:11299809 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11299809 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11299809 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11299809 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11299809 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11299809 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11299809 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11299809 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11299809 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:11299809 | pubmed:issn | 0250-7005 | lld:pubmed |
pubmed-article:11299809 | pubmed:author | pubmed-author:CastroAA | lld:pubmed |
pubmed-article:11299809 | pubmed:author | pubmed-author:MoroCC | lld:pubmed |
pubmed-article:11299809 | pubmed:author | pubmed-author:RoccaAA | lld:pubmed |
pubmed-article:11299809 | pubmed:author | pubmed-author:FerrettiGG | lld:pubmed |
pubmed-article:11299809 | pubmed:author | pubmed-author:NolèFF | lld:pubmed |
pubmed-article:11299809 | pubmed:author | pubmed-author:MunzoneEE | lld:pubmed |
pubmed-article:11299809 | pubmed:author | pubmed-author:CuriglianoGG | lld:pubmed |
pubmed-article:11299809 | pubmed:author | pubmed-author:MandalàMM | lld:pubmed |
pubmed-article:11299809 | pubmed:author | pubmed-author:CalabroM GMG | lld:pubmed |
pubmed-article:11299809 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:11299809 | pubmed:volume | 21 | lld:pubmed |
pubmed-article:11299809 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:11299809 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:11299809 | pubmed:pagination | 585-8 | lld:pubmed |
pubmed-article:11299809 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:11299809 | pubmed:meshHeading | pubmed-meshheading:11299809... | lld:pubmed |
pubmed-article:11299809 | pubmed:meshHeading | pubmed-meshheading:11299809... | lld:pubmed |
pubmed-article:11299809 | pubmed:meshHeading | pubmed-meshheading:11299809... | lld:pubmed |
pubmed-article:11299809 | pubmed:meshHeading | pubmed-meshheading:11299809... | lld:pubmed |
pubmed-article:11299809 | pubmed:meshHeading | pubmed-meshheading:11299809... | lld:pubmed |
pubmed-article:11299809 | pubmed:meshHeading | pubmed-meshheading:11299809... | lld:pubmed |
pubmed-article:11299809 | pubmed:meshHeading | pubmed-meshheading:11299809... | lld:pubmed |
pubmed-article:11299809 | pubmed:meshHeading | pubmed-meshheading:11299809... | lld:pubmed |
pubmed-article:11299809 | pubmed:meshHeading | pubmed-meshheading:11299809... | lld:pubmed |
pubmed-article:11299809 | pubmed:meshHeading | pubmed-meshheading:11299809... | lld:pubmed |
pubmed-article:11299809 | pubmed:meshHeading | pubmed-meshheading:11299809... | lld:pubmed |
pubmed-article:11299809 | pubmed:meshHeading | pubmed-meshheading:11299809... | lld:pubmed |
pubmed-article:11299809 | pubmed:meshHeading | pubmed-meshheading:11299809... | lld:pubmed |
pubmed-article:11299809 | pubmed:meshHeading | pubmed-meshheading:11299809... | lld:pubmed |
pubmed-article:11299809 | pubmed:meshHeading | pubmed-meshheading:11299809... | lld:pubmed |
pubmed-article:11299809 | pubmed:meshHeading | pubmed-meshheading:11299809... | lld:pubmed |
pubmed-article:11299809 | pubmed:meshHeading | pubmed-meshheading:11299809... | lld:pubmed |
pubmed-article:11299809 | pubmed:meshHeading | pubmed-meshheading:11299809... | lld:pubmed |
pubmed-article:11299809 | pubmed:meshHeading | pubmed-meshheading:11299809... | lld:pubmed |
pubmed-article:11299809 | pubmed:meshHeading | pubmed-meshheading:11299809... | lld:pubmed |
pubmed-article:11299809 | pubmed:meshHeading | pubmed-meshheading:11299809... | lld:pubmed |
pubmed-article:11299809 | pubmed:meshHeading | pubmed-meshheading:11299809... | lld:pubmed |
pubmed-article:11299809 | pubmed:meshHeading | pubmed-meshheading:11299809... | lld:pubmed |
pubmed-article:11299809 | pubmed:articleTitle | Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients. | lld:pubmed |
pubmed-article:11299809 | pubmed:affiliation | Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141-Milan, Italy. mario.mandala@ieo.it | lld:pubmed |
pubmed-article:11299809 | pubmed:publicationType | Journal Article | lld:pubmed |